Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Dupilumab improves symptoms, quality of life of patients with chronic nodular prurigo

19 Jun 2020

Use of dupilumab helps reduce itch and improve chronic nodular prurigo (CNPG) skin lesions, a recent study has shown.

“CNPG is a multifactorial skin disease characterized by itchy papules and nodules, usually resistant to standard treatment and associated with markedly impaired quality of life,” the author said.

This retrospective, multicentre study was conducted to assess the effectiveness and tolerability of dupilumab in treating adult patients with CNPG refractory to both topical and systemic therapies. Participants received dupilumab for at least 16 weeks.

Twenty-seven patients with CNPG achieved clinical improvement in terms of itch, skin lesions, sleeplessness, and quality of life. Of the participants, 24 (88.9 percent) had at least 16-week continuous treatment, and 11 of these patients (45.8 percent) had Investigator Global Assessment (IGA) score 1. Nineteen of 24 patients (79.2 percent) achieved at least a 2-grade reduction in IGA score.

At week 16, numeric rating scale values decreased from 8.9 to 2.7 for itch and from 8.2 to 1.7 for sleeplessness (p<0.001). Furthermore, 10 patients achieved 36 weeks of continuous treatment while maintaining clinical efficacy.

The study had several limitations, including a lack of validated assessment tools at the initial data collection, a limited cohort of treated patients, and a short-term observation period.

A recent study also reported the beneficial effects of dupilumab in patients with bullous pemphigoid, resulting in disease clearance or satisfactory response in several patients. [J Am Acad Dermatol 2020;83:46-52]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.